Pharmaceutical Technology's In the Lab eNewsletter
Intertek has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, UK, through the acquisition of a new 20,000 sq. ft facility.
Intertek, a provider of total quality assurance, has announced the expansion of its pharmaceutical services laboratory in Melbourn, near Cambridge, United Kingdom, through the acquisition of a new 20,000 sq. ft facility.
The new facility doubles the current footprint of the company’s laboratory and is under development. The newly expanded facility is expected to open towards the end of 2019 and should provide capacity for more than 100 additional employees, which the company will recruit over a four-year period, it was revealed in a May 1, 2019 press release.
This new facility is located adjacent to the company’s current good manufacturing practice (GMP) laboratory and will expand the inhalation and nasal testing resources. Additionally, it will provide a dedicated laboratory space that will focus on formulation development of inhaled biologics aimed at meeting the increasing demand from global clients.
“We are delighted to expand and invest in inhalation and nasal product testing for biologics and pharmaceuticals at our Melbourn site, as global demand grows for specialist contract laboratory services,” said Intertek UK & Eire chief executive Rob van Dorp. “This latest expansion brings increased capacity and flexibility and will help to deliver a superior customer service for our clients around the world. Integrated with the teams’ outstanding expertise in analytical and formulation support for the pharmaceutical, biotechnology, and drug delivery industries, we can effectively help our clients to meet milestones for their challenging pharmaceutical development programmes through our systemic, end-to-end Total Quality Assurance solutions.”
Source: Intertek
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.